ArticleNucleic acids research1991
The use of engineered E1A genes to transactivate the hCMV-MIE promoter in permanent CHO cell lines.
Article in Nucleic acids research, 1991. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 68 citations in OpenAlex.
- CXCL17 binds efficaciously to glycosaminoglycans with the potential to modulate chemokine signaling.Frontiers in immunology · 2023Article
- Large-scale transfection of mammalian cells for the fast production of recombinant protein.Molecular biotechnology · 2006Review
- Gene transfer effects on various cationic amphiphiles in CHO cells.Cytotechnology · 2006Article
- Optimizing radiolabeled engineered anti-p185HER2 antibody fragments for in vivo imaging.Cancer research · 2005Article
- A specific alpha5beta1-integrin conformation promotes directional integrin translocation and fibronectin matrix formation.Journal of cell science · 2005Article
- Advances in animal cell recombinant protein production: GS-NS0 expression system.Cytotechnology · 2000Article
- Characterization and polyanion-binding properties of purified recombinant prion protein.The Biochemical journal · 1999Article
- The N-terminal end of the CH2 domain of chimeric human IgG1 anti-HLA-DR is necessary for C1q, Fc gamma RI and Fc gamma RIII binding.Immunology · 1995Article
- Approaches to maximizing stable expression of alpha 1-antitrypsin in transformed CHO cells.Applied microbiology and biotechnology · 1994Article
- Constitutive and enhanced expression from the CMV major IE promoter in a defective adenovirus vector.Nucleic acids research · 1992Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vectors expressing adenovirus 5 E1A or a domain 2 mutant E1A were introduced into CHO-K1 cells in order to transactivate the hCMV-MIE promoter in transient and stable transfections. Expression from the hCMV promoter was efficiently activated by both wild-type and mutant E1A in contrast to other viral promoters such as the SV40 early promoter which are repressed by E1A. E1A genes expressed from a strong promoter were inhibitory to the growth of CHO cells. Nevertheless, by the use of a weaker promoter, it was possible to isolate stably transfected cell lines containing a level of E1A compatible with both continued cell growth and significant transactivation of the hCMV promoter. By this means we have generated cell lines secreting tissue inhibitor of metalloproteinases (TIMP) at levels approaching those previously attained using gene amplification. CHO cell lines constitutively expressing wild-type and mutant E1A genes have been derived which can serve as new host cell lines for transient expression and efficient stable expression without gene amplification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.